利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.023 秒)

    AGENTS FOR TREATING FLAVIVIRIDAE INFECTIONS
    1.
    发明申请
    AGENTS FOR TREATING FLAVIVIRIDAE INFECTIONS 审中-公开
    用于治疗感冒的药剂

    公开(公告)号：US20100135966A1

    公开(公告)日：2010-06-03

    申请号：US12624271

    申请日：2009-11-23

    申请人： Ulrich Schubert ,  Hans Will ,  Hüseyin Sirma

    发明人： Ulrich Schubert ,  Hans Will ,  Hüseyin Sirma

    IPC分类号： A61K35/12 ,  A61K31/40 ,  A61K31/336

    CPC分类号： A61K31/69 ,  A61K31/11 ,  A61K31/16 ,  A61K38/06

    摘要： The invention relates to agents for the treatment, therapy and inhibition of Flaviviridae virus infections, which agents comprise proteasome inhibitors as the active component. The agents which are used for inhibiting the release, maturation and replication of Flaviviridae comprise, as the active component in pharmaceutical preparations, substance classes which share the common property of inhibiting the 26S proteasome in cells. These substance classes include, in particular, proteasome inhibitors which affect the activities of the ubiquitin/proteasome pathway, in particular the enzymic activities of the 26S and the 20S proteasome complex. The application of the invention lies in the antiviral therapy of Flaviviridae infections, especially in preventing the establishment and maintenance of a chronic hepatitis C virus infection and a hepatopathogenesis which is associated therewith.

    摘要翻译： 本发明涉及用于治疗，治疗和抑制黄病毒科病毒感染的药剂，该药物包含作为活性成分的蛋白酶体抑制剂。 用于抑制黄病毒科的释放，成熟和复制的药物包含作为药物制剂中的活性成分的具有抑制细胞中26S蛋白酶体的共同性质的物质类别。 这些物质类别特别包括影响泛素/蛋白酶体途径的活性的蛋白酶体抑制剂，特别是26S和20S蛋白酶体复合物的酶活性。 本发明的应用在于黄病毒科感染的抗病毒治疗，特别是在预防慢性丙型肝炎病毒感染的建立和维持以及与之相关的肝癌发病。

    Agents for treating <I>flaviviridae</I>infections
    3.
    发明申请
    Agents for treating flaviviridaeinfections 审中-公开
    用于治疗黄病毒感染的药剂

    公开(公告)号：US20050203029A1

    公开(公告)日：2005-09-15

    申请号：US10510355

    申请日：2003-04-04

    申请人： Ulrich Schubert ,  Hans Will ,  Huseyin Sirma

    发明人： Ulrich Schubert ,  Hans Will ,  Huseyin Sirma

    IPC分类号： A61K31/11 ,  A61K31/16 ,  A61K31/69 ,  A61K38/06 ,  A61P31/12 ,  A61K31/366 ,  A61K38/04

    CPC分类号： A61K31/69 ,  A61K31/11 ,  A61K31/16 ,  A61K38/06

    摘要： The invention relates to agents for the treatment, therapy and inhibition of Flaviviridae virus infections, which agents comprise proteasome inhibitors as the active component. The agents which are used for inhibiting the release, maturation and replication of Flaviviridae comprise, as the active component in pharmaceutical preparations, substance classes which share the common property of inhibiting the 26S proteasome in cells. These substance classes include, in particular, proteasome inhibitors which affect the activities of the ubiquitin/proteasome pathway, in particular the enzymic activities of the 26S and the 20S proteasome complex. The application of the invention lies in the antiviral therapy of Flaviviridae infections, especially in preventing the establishment and maintenance of a chronic hepatitis C virus infection and a hepatopathogenesis which is associated therewith.

    摘要翻译： 本发明涉及用于治疗，治疗和抑制黄病毒科病毒感染的药剂，该药物包含作为活性成分的蛋白酶体抑制剂。 用于抑制黄病毒科的释放，成熟和复制的药物包含作为药物制剂中的活性成分的具有抑制细胞中26S蛋白酶体的共同性质的物质类别。 这些物质类别特别包括影响泛素/蛋白酶体途径的活性的蛋白酶体抑制剂，特别是26S和20S蛋白酶体复合物的酶活性。 本发明的应用在于黄病毒科感染的抗病毒治疗，特别是在预防慢性丙型肝炎病毒感染的建立和维持以及与之相关的肝癌发病。

    Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases
    4.
    发明申请
    Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases 审中-公开
    β-L-核苷及其用作治疗病毒性疾病的药剂

    公开(公告)号：US20060217345A1

    公开(公告)日：2006-09-28

    申请号：US11373062

    申请日：2006-03-10

    申请人： Eckart Matthes ,  Martin Janta-Lipinski ,  Hans Will ,  Huseyin Sirma ,  Lin Li

    发明人： Eckart Matthes ,  Martin Janta-Lipinski ,  Hans Will ,  Huseyin Sirma ,  Lin Li

    IPC分类号： A61K31/7072 ,  A61K31/675 ,  A61K31/513 ,  C07H19/04 ,  C07H19/12 ,  C07F9/6512

    CPC分类号： C07H19/06 ,  C07H19/09

    摘要： Nucleoside analogs, nucleic acids and pharmaceutical agents comprising same, and to the use of said nucleoside analogs, nucleic acids and pharmaceutical agents in the diagnosis, prophylaxis or therapy of a viral, bacterial, fungicidal and/or parasitic infection, or of cancer, particularly of hepatitis infections. The invention also relates to a method for the preparation of said nucleoside analogs and to a kit and the use thereof in the prophylaxis and therapy of viral diseases, particularly of hepatitis infections. As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

    摘要翻译： 核苷类似物，核酸和包含其的药物，以及所述核苷类似物，核酸和药物在诊断，预防或治疗病毒，细菌，杀真菌和/或寄生虫感染或癌症中的用途，特别是 的肝炎感染。 本发明还涉及制备所述核苷类似物和试剂盒的方法及其用于预防和治疗病毒性疾病，特别是肝炎感染的用途。 如37 C.F.R. §1.72（b）：说明书中技术性披露的简要摘要必须在单独的表格上开始，优选按照权利要求，在“披露摘要”标题下。 摘要的目的是使专利商标局和公众一般能够从粗略检查中快速确定技术披露的性质和要点。 摘要不得用于解释权利要求的范围。 因此，与摘要有关的任何陈述不旨在以任何方式限制权利要求，也不应被解释为以任何方式限制权利要求。